首页|盐酸度洛西汀联合坦度螺酮治疗COPD合并焦虑及抑郁患者的临床观察

盐酸度洛西汀联合坦度螺酮治疗COPD合并焦虑及抑郁患者的临床观察

扫码查看
目的 探究盐酸度洛西汀联合坦度螺酮治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并焦虑及抑郁患者的临床观察。方法 选取 2017 年 3 月至 2022 年 9 月如皋市人民医院收治的 82 例COPD合并焦虑及抑郁患者,采用随机数字表法分为观察组和对照组,各 41 例。对照组给予盐酸度洛西汀 40 mg/d(20 mg/次,2 次/d),观察组在给予盐酸度洛西汀的同时服用坦度螺酮 30 mg/d(10 mg/次,3 次/d)。连续治疗 8 周后,评估患者临床疗效、焦虑及抑郁程度,检测患者肺功能指标、神经递质分泌水平,统计患者药物不良反应,观察治疗方案的安全性。结果 观察组、对照组患者的治疗总有效率分别为 95。12%(39/41)、78。05%(32/41),且观察组治疗高于对照组(P<0。05)。2 组患者治疗后汉密尔顿抑郁量表(Hamilton depression scale,HAMD)、汉密尔顿焦虑量表(Hamilton anxiety scale,HAMA)及匹兹堡睡眠质量指数量表(Pittsburgh sleep quality index,PSQI)评分降低,且观察组HAMD、HAMA及PSQI评分均低于对照组(P<0。05)。2 组患者治疗后神经生长因子(nerve growth factor,NGF)、5-羟色胺(5-hydroxytryptamine,5-HT)水平均升高,且观察组较对照组高(P<0。05)。2 组患者治疗后第 1 秒用力呼气量(forced expiratory volume in the first second,FEV1)及 FEV1/用力肺活量(forced expiratory volume,FVC)均较治疗前升高(P<0。05),组间FEV1、FEV1/FVC及治疗前后差值比较,差异无统计学意义(P>0。05)。观察组、对照组患者的不良反应发生率分别为 24。39%(10/41)、14。63%(6/41),二者比较,差异无统计学意义(P>0。05)。结论 盐酸度洛西汀联合坦度螺酮提高COPD合并焦虑抑郁患者的疗效,提高神经递质分泌水平,改善焦虑及抑郁程度。
Effect of duloxetine hydrochloride combined with tandospirone on anxiety and depression in COPD patients
Objective To explore the clinical effect of duloxetine hydrochloride combined with tandospirone in the treatment of anxiety and depression in patients with chronic obstructive pulmonary disease(COPD).Methods A total of 82 COPD patients with anxiety and depression who were admitted to The People's Hospital of Rugao from March 2017 to September 2022 were enrolled and divided into two groups by random number table,with 41 cases in each group.The control group was given duloxetine hydrochloride(40 mg/d,20 mg each time,bid),and the observation group was given duloxetine hydrochloride(40 mg/d,20 mg each time,bid)and tandospirone(30 mg/d,10 mg each time,tid)for 8 weeks.The clinical efficacy,the degree of anxiety and depression,lung function,neurotransmitter levels,adverse drug reactions,and the safety of therapeutic regimens were evaluated.Results The total effective rate of the observation group was significantly higher than that of the control group(95.12%[39/41]vs 78.05%[32/41],P<0.05).Hamilton depression scale(HAMD)score,Hamilton anxiety scale(HAMA)score,and Pittsburgh sleep quality index(PSQI)were decreased after treatment in both groups,and these scores in the observation group were lower than those in the control group(all P<0.05).After treatment,the levels of nerve growth factor(NGF)and 5-hydroxytryptamine(5-HT)in both groups were increased,and BDNF and 5-HT in the observation group were higher than those in the control group(all P<0.05).The forced expiratory volume in the first second(FEV1)and the ratio of FEV1 to forced vital capacity(FEV)after treatment were higher than those before treatment(P<0.05).There were no significant differences in FEV1 or FEV1/FVC between groups after treatment(P>0.05).The adverse reaction rates of observation group and control group were 24.39%(10/41)and 14.63%(6/41),respectively(P>0.05).Conclusion Duloxetine hydrochloride combined with tandospirone can increase neurotransmitter levels and improve the degree of anxiety and depression in COPD patients.

Duloxetine hydrochlorideTandospironeChronic obstructive pulmonary diseaseAnxiety and depression

曹海燕、储祥健、陈龙

展开 >

226500 江苏南通,如皋市人民医院呼吸与危重症医学科

226500 江苏南通,如皋市人民医院放疗科

盐酸度洛西汀 坦度螺酮 慢性阻塞性肺疾病 焦虑抑郁

2024

海军医学杂志
海军医学研究所

海军医学杂志

CSTPCD
影响因子:0.518
ISSN:1009-0754
年,卷(期):2024.45(6)
  • 15